| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Cellular Genetics Unit, Institute of Cellular Pathology, and
Laboratory of Human Molecular Genetics, Institute of Cellular Pathology, Université catholique de Louvain, Brussels, Belgium; and
Ludwig Institute for Cancer Research, Brussels, Belgium
We have identified an Ag recognized by autologous CTL on the melanoma cells of a patient who enjoyed an unusually favorable clinical evolution. The antigenic peptide, which is presented by HLA-A28 molecules, is encoded by a mutated sequence in a new gene. This gene, which was named MUM-3, is expressed ubiquitously and shows homology with the RNA helicase gene family. Limiting dilution analysis indicated that at least 0.15% of the blood CD8 T cells were tumor-specific CTL precursors. The MUM-3 Ag was recognized by 90% of these CTL, indicating that it is the dominant target Ag of the tumor-specific CTL response. The high frequency of anti-MUM-3 CTL was confirmed with tetramers of soluble HLA-A28 molecules loaded with the antigenic peptide. MUM-3 tetramers stained 1.2% of blood CD8 cells, a frequency that has never been reported for T cells directed against a strictly tumor-specific Ag. To confirm these results, the CD8 T cells that were clearly labeled with tetramers were restimulated in clonal conditions. About 90% of these cells proliferated, and all the resulting clones proved lytic and MUM-3 specific. By improving the conditions used for the in vitro restimulation of CTL precursors by the tumor cells, the same frequency could be obtained in limiting dilution analysis. These results show that some cancer patients have a high frequency of circulating CTL that are directed against a strictly tumor-specific Ag. These CTL are responsive to restimulation in vitro and are easily detected with tetramers. Such responses may therefore be an achievable goal for therapeutic vaccination with tumor-specific Ags.
This article has been cited by other articles:
|
|
 |
|
  G. Parmiani, A. De Filippo, L. Novellino, and C. Castelli Unique Human Tumor Antigens: Immunobiology and Use in Clinical Trials J. Immunol., February 15, 2007; 178(4): 1975 - 1979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Udagawa, C. Kudo-Saito, G. Hasegawa, K. Yano, A. Yamamoto, M. Yaguchi, M. Toda, I. Azuma, T. Iwai, and Y. Kawakami Enhancement of Immunologic Tumor Regression by Intratumoral Administration of Dendritic Cells in Combination with Cryoablative Tumor Pretreatment and Bacillus Calmette-Guerin Cell Wall Skeleton Stimulation Clin. Cancer Res., December 15, 2006; 12(24): 7465 - 7475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sensi and A. Anichini Unique Tumor Antigens: Evidence for Immune Control of Genome Integrity and Immunogenic Targets for T Cell-Mediated Patient-Specific Immunotherapy Clin. Cancer Res., September 1, 2006; 12(17): 5023 - 5032. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Goto, Y. Matsuzaki, S. Kurihara, A. Shimizu, T. Okada, K. Yamamoto, H. Murata, M. Takata, H. Aburatani, D. S.B. Hoon, et al. A new melanoma antigen Fatty Acid-binding protein 7, involved in proliferation and invasion, is a potential target for immunotherapy and molecular target therapy. Cancer Res., April 15, 2006; 66(8): 4443 - 4449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Somasundaram, R. Swoboda, L. Caputo, L. Otvos, B. Weber, P. Volpe, P. van Belle, S. Hotz, D. E. Elder, F. M. Marincola, et al. Human Leukocyte Antigen-A2-Restricted CTL Responses to Mutated BRAF Peptides in Melanoma Patients. Cancer Res., March 15, 2006; 66(6): 3287 - 3293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Filaci, M. Fravega, M. Setti, P. Traverso, E. Millo, D. Fenoglio, S. Negrini, F. Ferrera, A. Romagnoli, M. Basso, et al. Frequency of telomerase-specific CD8+ T lymphocytes in patients with cancer Blood, February 15, 2006; 107(4): 1505 - 1512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Luiten, E. W.M. Kueter, W. Mooi, M. P.W. Gallee, E. M. Rankin, W. R. Gerritsen, S. M. Clift, W. J. Nooijen, P. Weder, W. F. van de Kasteele, et al. Immunogenicity, Including Vitiligo, and Feasibility of Vaccination With Autologous GM-CSF-Transduced Tumor Cells in Metastatic Melanoma Patients J. Clin. Oncol., December 10, 2005; 23(35): 8978 - 8991. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Iwata, T. Fujita, N. Hirao, Y. Matsuzaki, T. Okada, H. Mochimaru, N. Susumu, E. Matsumoto, K. Sugano, N. Yamashita, et al. Frequent Immune Responses to a Cancer/Testis Antigen, CAGE, in Patients with Microsatellite instability-Positive Endometrial Cancer Clin. Cancer Res., May 15, 2005; 11(10): 3949 - 3957. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sensi, G. Nicolini, M. Zanon, C. Colombo, A. Molla, I. Bersani, R. Lupetti, G. Parmiani, and A. Anichini Immunogenicity without Immunoselection: A Mutant but Functional Antioxidant Enzyme Retained in a Human Metastatic Melanoma and Targeted by CD8+ T Cells with a Memory Phenotype Cancer Res., January 15, 2005; 65(2): 632 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Purev, D. Cai, E. Miller, R. Swoboda, T. Mayer, A. Klein-Szanto, F. M. Marincola, R. Mick, L. Otvos, W. Wunner, et al. Immune Responses of Breast Cancer Patients to Mutated Epidermal Growth Factor Receptor (EGF-RvIII, {Delta}EGF-R, and de2-7 EGF-R) J. Immunol., November 15, 2004; 173(10): 6472 - 6480. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Andersen, J. Fensterle, S. Ugurel, S. Reker, R. Houben, P. Guldberg, T. G. Berger, D. Schadendorf, U. Trefzer, E.-B. Brocker, et al. Immunogenicity of Constitutively Active V599EBRaf Cancer Res., August 1, 2004; 64(15): 5456 - 5460. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Spaner Amplifying cancer vaccine responses by modifying pathogenic gene programs in tumor cells J. Leukoc. Biol., August 1, 2004; 76(2): 338 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Novellino, N. Renkvist, F. Rini, A. Mazzocchi, L. Rivoltini, A. Greco, P. Deho, P. Squarcina, P. F. Robbins, G. Parmiani, et al. Identification of a Mutated Receptor-Like Protein Tyrosine Phosphatase {kappa} as a Novel, Class II HLA-Restricted Melanoma Antigen J. Immunol., June 15, 2003; 170(12): 6363 - 6370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Gitelson, C. Hammond, J. Mena, M. Lorenzo, R. Buckstein, N. L. Berinstein, K. Imrie, and D. E. Spaner Chronic Lymphocytic Leukemia-reactive T Cells during Disease Progression and after Autologous Tumor Cell Vaccines Clin. Cancer Res., May 1, 2003; 9(5): 1656 - 1665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Echchakir, G. Dorothee, I. Vergnon, J. Menez, S. Chouaib, and F. Mami-Chouaib Cytotoxic T lymphocytes directed against a tumor-specific mutated antigen display similar HLA tetramer binding but distinct functional avidity and tissue distribution PNAS, July 9, 2002; 99(14): 9358 - 9363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Parmiani, C. Castelli, P. Dalerba, R. Mortarini, L. Rivoltini, F. M. Marincola, and A. Anichini Cancer Immunotherapy With Peptide-Based Vaccines: What Have We Achieved? Where Are We Going? J Natl Cancer Inst, June 5, 2002; 94(11): 805 - 818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Linard, S. Bezieau, H. Benlalam, N. Labarriere, Y. Guilloux, E. Diez, and F. Jotereau A ras-Mutated Peptide Targeted by CTL Infiltrating a Human Melanoma Lesion J. Immunol., May 1, 2002; 168(9): 4802 - 4808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. F. Greten and J. P. Schneck Development and Use of Multimeric Major Histocompatibility Complex Molecules Clin. Vaccine Immunol., March 1, 2002; 9(2): 216 - 220. [Full Text] [PDF]
|
|
|
|
|
|
D. Valmori, C. Scheibenbogen, V. Dutoit, D. Nagorsen, A. M. Asemissen, V. Rubio-Godoy, D. Rimoldi, P. Guillaume, P. Romero, D. Schadendorf, et al. Circulating Tumor-reactive CD8+ T Cells in Melanoma Patients Contain a CD45RA+CCR7- Effector Subset Exerting ex Vivo Tumor-specific Cytolytic Activity Cancer Res., March 1, 2002; 62(6): 1743 - 1750. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kiniwa, T. Fujita, M. Akada, K. Ito, T. Shofuda, Y. Suzuki, A. Yamamoto, T. Saida, and Y. Kawakami Tumor Antigens Isolated from a Patient with Vitiligo and T-Cell-infiltrated Melanoma Cancer Res., November 1, 2001; 61(21): 7900 - 7907. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. B. Beck-Engeser, P. A. Monach, D. Mumberg, F. Yang, S. Wanderling, K. Schreiber, R. Espinosa III, M. M. Le Beau, S. C. Meredith, and H. Schreiber Point Mutation in Essential Genes with Loss or Mutation of the Second Allele: Relevance to the Retention of Tumor-Specific Antigens J. Exp. Med., August 6, 2001; 194(3): 285 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Karanikas, D. Colau, J.-F. Baurain, R. Chiari, J. Thonnard, I. Gutierrez-Roelens, C. Goffinet, E. V. Schaftingen, P. Weynants, T. Boon, et al. High Frequency of Cytolytic T Lymphocytes Directed against a Tumor-specific Mutated Antigen Detectable with HLA Tetramers in the Blood of a Lung Carcinoma Patient with Long Survival Cancer Res., May 1, 2001; 61(9): 3718 - 3724. [Abstract] [Full Text]
|
|
|
|
|
|
H. Echchakir, F. Mami-Chouaib, I. Vergnon, J.-F. Baurain, V. Karanikas, S. Chouaib, and P. G. Coulie A Point Mutation in the {{alpha}}-Actinin-4 Gene Generates an Antigenic Peptide Recognized by Autologous Cytolytic T Lymphocytes on a Human Lung Carcinoma Cancer Res., May 1, 2001; 61(10): 4078 - 4083. [Abstract] [Full Text]
|
|
|
|
|
|
R. Chiari, G. Hames, V. Stroobant, C. Texier, B. Maillère, T. Boon, and P. G. Coulie Identification of a Tumor-specific Shared Antigen Derived From an Eph Receptor and Presented to CD4 T Cells on HLA Class II Molecules Cancer Res., September 1, 2000; 60(17): 4855 - 4863. [Abstract] [Full Text]
|
|
|
|
|
|
P. G. Coulie, V. Karanikas, D. Colau, C. Lurquin, C. Landry, M. Marchand, T. Dorval, V. Brichard, and T. Boon A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3 PNAS, August 28, 2001; 98(18): 10290 - 10295. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
